FDA Approves Gedatolisib With Fulvestrant, With Or Without Palbociclib, For Hr-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer
Celcuity Inc.
Celcuity Inc. CELC | 0.00 |
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-gedatolisib-fulvestrant-or-without-palbociclib-hr-positive-her2-negative-locally